STOK Stoke Therapeutics Inc
828
$15.81
$0.46
(3.00%)
| Watchers | 828 |
| 52-Wk Low | $3.35 |
| 52-Wk High | $16.66 |
| Market Cap | $824.02M |
| Volume | 823,509.00 |
| 52-Wk High | $16.66 |
| 52-Wk Low | $3.35 |
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business Wire • 5 days ago
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
Share to Feed
Latest Ratings for STOK
DateFirmActionFromTo Jan 2022JefferiesInitiates Coverage OnBuy Dec 2021B of A SecuritiesInitiates Coverage OnBuy Nov 2021JP MorganUpgradesNeutralOverweight
View More...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today...
Investors eyeing a purchase of Stoke Therapeutics Inc (STOK) stock, but cautious about paying the going market price of 12.82/share, might benefit from considering selling puts among the...
Stoke Therapeutics (NASDAQ:STOK - Get Free Report)s stock had its "overweight" rating reiterated by stock analysts at Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga...
Latest Ratings for STOK
DateFirmActionFromTo Jan 2022JefferiesInitiates Coverage OnBuy Dec 2021B of A SecuritiesInitiates Coverage OnBuy Nov 2021JP MorganUpgradesNeutralOverweight
View More...
Leerink Partners analyst Rudy Li has maintained their bullish stance on STOK stock, giving a Buy rating on March 26. Rudy Li has given his Buy rati...